Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin + XMT-1536 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
XMT-1536 | XMT1536|XMT 1536|Upifitamab Rilsodotin|Anti-NaPi2b ADC XMT-1536 | XMT-1536 is an anti-type II sodium-dependent potassium transporter (NaPi2b) antibody in conjugation with cytotoxic auristatin molecules, which delivers auristatin to tumor cells over expressing NaPi2b and results in tumor cell death (Proceedings of AACR, Vol 57, Apr 2016, Abstract # 1194). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04907968 | Phase Ib/II | Carboplatin + XMT-1536 | Study of Upifitamab Rilsodotin in Combination With Other Agent(s) in Participants With High-grade Serous Ovarian Cancer (UPGRADE) | Terminated | USA | 0 |